Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01340664 · ClinicalTrials.gov registry record · Phase 2
An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 279
- Enrollment target
NCT01340664 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 279 participants.
The verdict
NCT01340664, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 279 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in patients with type 2 diabetes mellitus who are receiving treatment with metformin monotherapy (ie, treatment with a single drug) and have inadequate glycemic (blood sugar) control.
Interventions
- DRUG Placebo
- DRUG Metformin
- DRUG Canagliflozin 50 mg
- DRUG Canagliflozin 150 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 279 participants |
| Start Date | 2011-07 |
| Est. Completion | 2012-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01340664
The ClinicalTrials.gov registry entry for NCT01340664 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 279 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01340664 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01340664 about?
NCT01340664 is a clinical study titled "An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy". The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in patients with type 2 diabetes mellitus who are receiving treatment with metformin monotherapy (ie, treatment with a single drug) and have inadequate glycemic (blood sugar) ...
What is the current status of trial NCT01340664?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 279 participants. The study started on 2011-07. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01340664?
The interventions under investigation include: Placebo (DRUG), Metformin (DRUG), Canagliflozin 50 mg (DRUG), Canagliflozin 150 mg (DRUG).
Who is sponsoring clinical trial NCT01340664?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.